Skip to main content

Table 2 Ongoing studies on PD1 inhibitors and radiation therapy in HNSCC

From: PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

Abbreviated Trial Name/NCT#

Phase

Agent(s)

Study population

Expected Primary Endpoint

NCT01935921

Ib

Cetuximab, ipilimumab and IMRT

stage III-IVa

HPV+ OPSCC

Dose limiting toxicities (DLT)

RTOG 3504

NCT02764593

III w/phase I lead in

Nivolumab and cisplatin CRT

stage III-IV, intermediate to high risk HNSCC

DLT for phase I

NCT02777385

II

Concurrent vs sequential pembro, cisplatin and IMRT

stage III-IVb

HNSCC

1 year PFS

1 year failure rate

Acute toxicity rates

HN003

NCT02775812

I

Adjuvant pembro, cisplatin and IMRT

high risk stage III-IV HSNCC

DLT

NCT02641093

II

Adjuvant pembro, cisplatin and IMRT

high risk stage III-IV HSNCC

Treatment related adverse events (TRAE)

Disease free survival (DFS)